Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction

Malin Christersson1, Stefan Gustafsson2, Erik Lampa1

  • 1Department of Medical Sciences Uppsala University Uppsala Sweden.

Insights

New heart failure guidelines created a mildly reduced ejection fraction category, but LVEF is highly variable. This category is unstable, with patients frequently changing LVEF status within a year.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Medical Guidelines

Background:

  • Recent heart failure guidelines introduced a new category: heart failure with mildly reduced ejection fraction (LVEF 41%-49%).
  • This category sits between heart failure with reduced ejection fraction (LVEF ≤40%) and heart failure with preserved ejection fraction (LVEF ≥50%).
  • Categorizing continuous measurements with high variability can be problematic.

Purpose of the Study:

  • To assess the variability and stability of left ventricular ejection fraction (LVEF) categories in heart failure patients.
  • To evaluate the clinical implications of the newly introduced heart failure with mildly reduced ejection fraction category.

Main Methods:

  • A cohort of 9716 new chronic heart failure cases with available LVEF in Stockholm (2015-2020) was analyzed.
  • Mixed models quantified within-person LVEF variance; multistate Markov models assessed LVEF category stability.
  • Patient LVEF values were tracked over time, with follow-up until death or study end.

Main Results:

  • Left ventricular ejection fraction (LVEF) followed a normal distribution with a significant within-person standard deviation of 7.4%.
  • The mean time spent in any LVEF category was less than one year for heart failure with mildly reduced ejection fraction.
  • There was a substantial probability of transitioning between LVEF categories within the first year; <25% of patients with mildly reduced LVEF remained in that category after one year.

Conclusions:

  • Left ventricular ejection fraction (LVEF) exhibits considerable variability over time, challenging the stability of narrow diagnostic categories.
  • The heart failure with mildly reduced ejection fraction category is particularly inconstant, with frequent LVEF fluctuations.
  • Clinical decisions and treatment strategies should account for the inherent variability and normal distribution of LVEF in heart failure patients.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577